News
FDA asks Sarepta to stop shipping gene therapy
Digest more
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results